Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood (2025) 146 (15): 1747–1758.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Journal Articles

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Blood blood.2025030113.

https://doi.org/10.1182/blood.2025030113

Published: 2025

Includes: Supplemental data

Journal Articles

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Blood blood.2025029360.

https://doi.org/10.1182/blood.2025029360

Published: 2025

Includes: Supplemental data

Journal Articles

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Blood (2025) 146 (8): 964–970.

https://doi.org/10.1182/blood.2025029234

Published: 2025

Includes: Supplemental data

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau

Blood (2024) 144 (Supplement 1): 4757.1.

https://doi.org/10.1182/blood-2024-199752

Published: 2024

Journal Articles

An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Blood (2024) 144 (Supplement 1): 670.

https://doi.org/10.1182/blood-2024-194041

Published: 2024

Journal Articles

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Blood (2024) 144 (Supplement 1): 497.

https://doi.org/10.1182/blood-2024-198669

Published: 2024

Journal Articles

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Paula Rodríguez-Otero, Joshua Richter, Ajay K. Nooka, Fredrik Schjesvold, Emily Combe, Leanne Cooper, Ollie Schofield, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Simon McNamara, Molly Purser

Blood (2024) 144 (Supplement 1): 7054.

https://doi.org/10.1182/blood-2024-198712

Published: 2024

Journal Articles

Large B-Cell Lymphoma in Elderly Patients: Completing Treatment Showed Impact on Overall Survival, a Real World Evidence

Victoria Wauters, Carolina Valeria Mahuad, Gonzalo Martin Garate, Maria De Los Angeles Vicente Reparaz, Florencia Aizpurua, Marta Elisa Zerga, Paula Rodriguez-Otero, Martina Rodriguez, Claudia Casali, Manuela Clavijo

Blood (2024) 144 (Supplement 1): 6440.

https://doi.org/10.1182/blood-2024-208904

Published: 2024

Journal Articles

Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma

Surbhi Sidana, Christof Scheid, Peter J. Mueller, Petra Schuberth, Hardik Modi, Peter Krengel, Romain Piault, Xiaobo Zhong, Paula Rodríguez-Otero

Blood (2024) 144 (Supplement 1): 3476.

https://doi.org/10.1182/blood-2024-194645

Published: 2024

Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Blood (2024) 144 (Supplement 1): 487.

https://doi.org/10.1182/blood-2024-199550

Published: 2024

Journal Articles

Identification and Evaluation of Novel Sdab-Based CAR-T Cells Against BCMA with Improved Therapeutic Efficacy for Multiple Myeloma

Vianca Ibarra-Garcia, Eva Molina, Franco Bernasconi-Bisio, Federica Rochira, Saray Rodríguez Diaz, Rebeca Martínez Turrillas, Paula Rodriguez-Marquez, Patricia Jauregui, Lucia Vanrell, Sara Villar, Paula Rodríguez-Otero, Juan J Lasarte, Juan Roberto Rodriguez-Madoz, Felipe Prosper, Antonio Pineda-Lucena

Blood (2024) 144 (Supplement 1): 7155.

https://doi.org/10.1182/blood-2024-208103

Published: 2024

Journal Articles

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2024-205481

Published: 2024

Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Blood (2024) 144 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2024-199542

Published: 2024

Journal Articles

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Blood (2024) 144 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2024-211383

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2024-204614

Published: 2024

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Enrique M Ocio, Aurore Perrot, Pierre Bories, Jesús F. San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Song-Yau Wang, Sara Bringhen, Maria-Victoria Mateos, Paula Rodríguez-Otero, Stefania Oliva, Axel Nogai, Bruno Paiva, Yi Li, Eric Le Bras, Sandrine Macé, Ercem Kodas, Helgi Van de Velde, Philippe Moreau

Blood (2024) 144 (Supplement 1): 1976.

https://doi.org/10.1182/blood-2024-200135

Published: 2024

Journal Articles

Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Blood (2024) 144 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2024-201435

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Large B-Cell Lymphoma in Elderly Patients: Completing Treatment Showed Impact on Overall Survival, a Real World Evidence

Global Manufacturing Experience with Idecabtagene Vicleucel in Patients with Relapsed and Refractory Multiple Myeloma

Identification and Evaluation of Novel Sdab-Based CAR-T Cells Against BCMA with Improved Therapeutic Efficacy for Multiple Myeloma

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study

Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only